{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:32:57Z","timestamp":1790875977798,"version":"4.1.0"},"reference-count":55,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Agonistic anti-Fas antibodies and multimeric recombinant Fas ligand (FasL) preparations show high tumoricidal activity against leukemic cells, but are unsuitable for clinical application due to unacceptable systemic toxicity. Consequently, new antileukemia strategies based on Fas activation have to meet the criterion of strictly localized action at the tumor-cell surface. Recent insight into the FasL\/Fas system has revealed that soluble homotrimeric FasL (sFasL) is in fact nontoxic to normal cells, but also lacks tumoricidal activity. We report on a novel fusion protein, designated scFvCD7:sFasL, that is designed to have leukemia-restricted activity. ScFvCD7:sFasL consists of sFasL genetically linked to a high-affinity single-chain fragment of variable regions (scFv) antibody fragment specific for the T-cell leukemia-associated antigen CD7. Soluble homotrimeric scFvCD7:sFasL is inactive and acquires tumoricidal activity only after specific binding to tumor cell-surface-expressed CD7. Treatment of T-cell acute lymphoblastic leukemia (T-ALL) cell lines and patient-derived T-ALL, peripheral T-cell lymphoma (PTCL), and CD7-positive acute myeloid leukemia (AML) cells with homotrimeric scFvCD7:sFasL revealed potent CD7-restricted induction of apoptosis that was augmented by conventional drugs, farnesyl transferase inhibitor L-744832, and the proteasome inhibitor bortezomib (Velcade; Millenium, Cambridge, MA). Importantly, identical treatment did not affect normal human peripheral-blood lymphocytes (PBLs) and endothelial cells, with only moderate apoptosis in interleukin-2 (IL-2)\/CD3-activated T cells. CD7-restricted activation of Fas in T-cell leukemic cells by scFvCD7:sFasL revitalizes interest in the applicability of Fas signaling in leukemia therapy.<\/jats:p>","DOI":"10.1182\/blood-2005-07-2929","type":"journal-article","created":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T03:13:44Z","timestamp":1133925224000},"page":"2863-2870","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":42,"title":["CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia"],"prefix":"10.1182","volume":"107","author":[{"given":"Edwin","family":"Bremer","sequence":"first","affiliation":[{"name":"From the Groningen University Institute for Drug Exploration (GUIDE), Department of Pathology & Laboratory Medicine, Medical Biology Section, Laboratory for Tumor Immunology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram ten","family":"Cate","sequence":"additional","affiliation":[{"name":"From the Groningen University Institute for Drug Exploration (GUIDE), Department of Pathology & Laboratory Medicine, Medical Biology Section, Laboratory for Tumor Immunology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douwe F.","family":"Samplonius","sequence":"additional","affiliation":[{"name":"From the Groningen University Institute for Drug Exploration (GUIDE), Department of Pathology & Laboratory Medicine, Medical Biology Section, Laboratory for Tumor Immunology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lou F. M. H.","family":"de Leij","sequence":"additional","affiliation":[{"name":"From the Groningen University Institute for Drug Exploration (GUIDE), Department of Pathology & Laboratory Medicine, Medical Biology Section, Laboratory for Tumor Immunology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wijnand","family":"Helfrich","sequence":"additional","affiliation":[{"name":"From the Groningen University Institute for Drug Exploration (GUIDE), Department of Pathology & Laboratory Medicine, Medical Biology Section, Laboratory for Tumor Immunology, University Medical Center Groningen (UMCG), University of Groningen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111816075708900_REF1","unstructured":"Jaffe E, Harris NL, Stein H, Vardiman L. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"2019111816075708900_REF2","unstructured":"Gramatzki M, Burger R, Strobel G, et al. Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia. 1995;9: 382-390."},{"key":"2019111816075708900_REF3","doi-asserted-by":"crossref","unstructured":"Baum W, Steininger H, Bair HJ, et al. Therapy with CD7 monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol. 1996;95: 327-338.","DOI":"10.1046\/j.1365-2141.1996.d01-1900.x"},{"key":"2019111816075708900_REF4","unstructured":"Peipp M, Kupers H, Saul D, et al. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 2002;62: 2848-2855."},{"key":"2019111816075708900_REF5","doi-asserted-by":"crossref","unstructured":"Frankel AE, Laver JH, Willingham MC, et al. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leuk Lymphoma. 1997;26: 287-298.","DOI":"10.3109\/10428199709051778"},{"key":"2019111816075708900_REF6","doi-asserted-by":"crossref","unstructured":"De Keersmaecker K, Graux C, Odero M, et al. Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14)(q34;q32). Blood. 2005;105: 4849-4852.","DOI":"10.1182\/blood-2004-12-4897"},{"key":"2019111816075708900_REF7","doi-asserted-by":"crossref","unstructured":"Avramis I, Laug W, Sausville E, Avramis V. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and\/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines. Cancer Chemother Pharmacol. 2003;52: 307-318.","DOI":"10.1007\/s00280-003-0668-y"},{"key":"2019111816075708900_REF8","unstructured":"Yakes FM, Wamil B, Sun F, et al. CM101 treatment overrides tumor-induced immunoprivilege leading to apoptosis. Cancer Res. 2000;60: 5740-5746."},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Kalechman Y, Strassmann G, Albeck M, Sredni B. Up-regulation by ammonium trichloro(dioxoethylene-0,0\u2032) tellurate (AS101) of Fas\/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J Immunol. 1998;161: 3536-3542.","DOI":"10.4049\/jimmunol.161.7.3536"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Muller M, Strand S, Hug H, et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1\/Fas) receptor\/ligand system and involves activation of wild-type p53. J Clin Invest. 1997;99: 403-413.","DOI":"10.1172\/JCI119174"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Owen-Schaub LB, Zhang W, Cusack JC, et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas\/APO-1 expression. Mol Cell Biol. 1995;15: 3032-3040.","DOI":"10.1128\/MCB.15.6.3032"},{"key":"2019111816075708900_REF12","doi-asserted-by":"crossref","unstructured":"Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1\/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med. 1998;188: 2033-2045.","DOI":"10.1084\/jem.188.11.2033"},{"key":"2019111816075708900_REF13","doi-asserted-by":"crossref","unstructured":"Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 1995;14: 1129-1135.","DOI":"10.1002\/j.1460-2075.1995.tb07096.x"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys. 2002;408: 155-161.","DOI":"10.1016\/S0003-9861(02)00525-8"},{"key":"2019111816075708900_REF15","unstructured":"Mitsiades N, Yu WH, Poulaki V, Tsokos M, Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 2001;61: 577-581."},{"key":"2019111816075708900_REF16","doi-asserted-by":"crossref","unstructured":"Mariani SM, Matiba B, Baumler C, Krammer PH. Regulation of cell surface APO-1\/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol. 1995;25: 2303-2307.","DOI":"10.1002\/eji.1830250828"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Kayagaki N, Kawasaki A, Ebata T, et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182: 1777-1783.","DOI":"10.1084\/jem.182.6.1777"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Mariani SM, Matiba B, Sparna T, Krammer PH. Expression of biologically active mouse and human CD95\/APO-1\/Fas ligand in the baculovirus system. J Immunol Methods. 1996;193: 63-70.","DOI":"10.1016\/0022-1759(96)00051-8"},{"key":"2019111816075708900_REF19","doi-asserted-by":"crossref","unstructured":"Timmer T, de Vries EG, de Jong S. Fas receptor-mediated apoptosis: a clinical application? J Pathol. 2002;196: 125-134.","DOI":"10.1002\/path.1028"},{"key":"2019111816075708900_REF20","doi-asserted-by":"crossref","unstructured":"Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364: 806-809.","DOI":"10.1038\/364806a0"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Tanaka M, Suda T, Yatomi T, Nakamura N, Nagata S. Lethal effect of recombinant human Fas ligand in mice pretreated with Propionibacterium acnes. J Immunol. 1997;158: 2303-2309.","DOI":"10.4049\/jimmunol.158.5.2303"},{"key":"2019111816075708900_REF22","doi-asserted-by":"crossref","unstructured":"Rensing-Ehl A, Frei K, Flury R, et al. Local Fas\/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol. 1995;25: 2253-2258.","DOI":"10.1002\/eji.1830250821"},{"key":"2019111816075708900_REF23","doi-asserted-by":"crossref","unstructured":"Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 1989;245: 301-305.","DOI":"10.1126\/science.2787530"},{"key":"2019111816075708900_REF24","doi-asserted-by":"crossref","unstructured":"Shimizu M, Yoshimoto T, Nagata S, Matsuzawa A. A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochem Biophys Res Commun. 1996;228: 375-379.","DOI":"10.1006\/bbrc.1996.1669"},{"key":"2019111816075708900_REF25","doi-asserted-by":"crossref","unstructured":"Schneider P, Holler N, Bodmer JL, et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med. 1998;187: 1205-1213.","DOI":"10.1084\/jem.187.8.1205"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J Exp Med. 1997;186: 2045-2050.","DOI":"10.1084\/jem.186.12.2045"},{"key":"2019111816075708900_REF27","doi-asserted-by":"crossref","unstructured":"Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med. 1998;4: 31-36.","DOI":"10.1038\/nm0198-031"},{"key":"2019111816075708900_REF28","doi-asserted-by":"crossref","unstructured":"Samel D, Muller D, Gerspach J, et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J Biol Chem. 2003;278: 32077-32082.","DOI":"10.1074\/jbc.M304866200"},{"key":"2019111816075708900_REF29","doi-asserted-by":"crossref","unstructured":"Bremer E, Samplonius DF, Peipp M et al. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res. 2005;65: 3380-3388.","DOI":"10.1158\/0008-5472.CAN-04-2756"},{"key":"2019111816075708900_REF30","unstructured":"Miwa H, Nakase K, Kita K. Biological characteristics of CD7(+) acute leukemia. Leuk Lymphoma. 1996;21: 239-244."},{"key":"2019111816075708900_","unstructured":"Janossy G, Coustan-Smith E, Campana D. The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. Leukemia. 1989;3: 170-181."},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Shimamoto T, Ohyashiki JH, Ohyashiki K, et al. Clinical and biologic characteristics of CD7+ acute myeloid leukemia: our experience and literature review. Cancer Genet Cytogenet. 1994;73: 69-74.","DOI":"10.1016\/0165-4608(94)90185-6"},{"key":"2019111816075708900_REF33","doi-asserted-by":"crossref","unstructured":"Del Poeta G, Stasi R, Venditti A, et al. CD7 expression in acute myeloid leukemia. Leuk Lymphoma. 1995;17: 111-119.","DOI":"10.3109\/10428199509051710"},{"key":"2019111816075708900_REF34","doi-asserted-by":"crossref","unstructured":"Haynes BF, Denning SM, Singer KH, Kurtzberg J. Ontogeny of T-cell precursors: a model for the initial stages of human T-cell development. Immunol Today. 1989;10: 87-91.","DOI":"10.1016\/0167-5699(89)90232-6"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Barcena A, Muench MO, Galy AH, et al. Phenotypic and functional analysis of T-cell precursors in the human fetal liver and thymus: CD7 expression in the early stages of T- and myeloid-cell development. Blood. 1993;82: 3401-3414.","DOI":"10.1182\/blood.V82.11.3401.3401"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Chabannon C, Wood P, Torok-Storb B. Expression of CD7 on normal human myeloid progenitors. J Immunol. 1992;149: 2110-2113.","DOI":"10.4049\/jimmunol.149.6.2110"},{"key":"2019111816075708900_","doi-asserted-by":"crossref","unstructured":"Cicuttini FM, Martin M, Petrie HT, Boyd AW. A novel population of natural killer progenitor cells isolated from human umbilical cord blood. J Immunol. 1993;151: 29-37.","DOI":"10.4049\/jimmunol.151.1.29"},{"key":"2019111816075708900_REF38","doi-asserted-by":"crossref","unstructured":"Reinhold U, Liu L, Sesterhenn J, Schnautz S, Abken H. The CD7- T cell subset represents the majority of IL-5-secreting cells within CD4+CD. Clin Exp Immunol. 1996;106: 555-559.","DOI":"10.1046\/j.1365-2249.1996.d01-873.x"},{"key":"2019111816075708900_REF39","unstructured":"Waurzyniak B, Schneider EA, Tumer N, et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clin Cancer Res. 1997;3: 881-890."},{"key":"2019111816075708900_REF40","doi-asserted-by":"crossref","unstructured":"Vallera DA, Burns LJ, Frankel AE, et al. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. J Immunol Methods. 1996;197: 69-83.","DOI":"10.1016\/0022-1759(96)00127-5"},{"key":"2019111816075708900_REF41","doi-asserted-by":"crossref","unstructured":"Pauza ME, Doumbia SO, Pennell CA. Construction and characterization of human CD7-specific single-chain Fv immunotoxins. J Immunol. 1997;158: 3259-3269.","DOI":"10.4049\/jimmunol.158.7.3259"},{"key":"2019111816075708900_REF42","doi-asserted-by":"crossref","unstructured":"Elliott SR, Macardle PJ, Zola H. Removal of erythroid cells from umbilical cord blood mononuclear cell preparations using magnetic beads and a monoclonal antibody against glycophorin A. J Immunol Methods. 1998;217: 121-130.","DOI":"10.1016\/S0022-1759(98)00111-2"},{"key":"2019111816075708900_REF43","doi-asserted-by":"crossref","unstructured":"Mulder AB, Blom NR, Smit JW, et al. Basal tissue factor expression in endothelial cell cultures is caused by contaminating smooth muscle cells: reduction by using chymotrypsin instead of collagenase. Thromb Res. 1995;80: 399-411.","DOI":"10.1016\/0049-3848(95)00192-T"},{"key":"2019111816075708900_REF44","doi-asserted-by":"crossref","unstructured":"Bremer E, Kuijlen J, Samplonius D, et al. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int J Cancer. 2004;109: 281-290.","DOI":"10.1002\/ijc.11702"},{"key":"2019111816075708900_REF45","unstructured":"Frankfurt OS. Detection of apoptosis in leukemic and breast cancer cells with monoclonal antibody to single-stranded DNA. Anticancer Res. 1994;14: 1861-1869."},{"key":"2019111816075708900_REF46","doi-asserted-by":"crossref","unstructured":"Bremer E, Samplonius D, Kroesen, BJ et al. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia. 2004;6: 636-645.","DOI":"10.1593\/neo.04229"},{"key":"2019111816075708900_REF47","doi-asserted-by":"crossref","unstructured":"Holler N, Tardivel A, Kovacsovics-Bankowski M, et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol. 2003;23: 1428-1440.","DOI":"10.1128\/MCB.23.4.1428-1440.2003"},{"key":"2019111816075708900_REF48","doi-asserted-by":"crossref","unstructured":"Hudson P. Recombinant antibody constructs in cancer therapy. Current Opin Immunol. 1999;11: 548-557.","DOI":"10.1016\/S0952-7915(99)00013-8"},{"key":"2019111816075708900_REF49","doi-asserted-by":"crossref","unstructured":"Starling G, Bajorath J, Emswiler J, et al. Identification of amino acid residues important for ligand binding to Fas. J Exp Med. 1997;185: 1487-1492.","DOI":"10.1084\/jem.185.8.1487"},{"key":"2019111816075708900_REF50","doi-asserted-by":"crossref","unstructured":"Kortt AA, Lah M, Oddie GW, et al. Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng. 1997;10: 423-433.","DOI":"10.1093\/protein\/10.4.423"},{"key":"2019111816075708900_REF51","doi-asserted-by":"crossref","unstructured":"Pluckthun A, Pack P. New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology. 1997;3: 83-105.","DOI":"10.1016\/S1380-2933(97)00067-5"},{"key":"2019111816075708900_REF52","unstructured":"Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res. 1999;5: 611-615."},{"key":"2019111816075708900_REF53","doi-asserted-by":"crossref","unstructured":"Jedema I, Barge RM, Willemze R, Falkenburg JH. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G1 phase of the cell cycle and can be increased by interferon treatment. Leukemia. 2003;17: 576-584.","DOI":"10.1038\/sj.leu.2402844"},{"key":"2019111816075708900_REF54","doi-asserted-by":"crossref","unstructured":"Komada Y, Zhou YW, Zhang XL, et al. Fas receptor (CD95)-mediated apoptosis is induced in leukemic cells entering G1B compartment of the cell cycle. Blood. 1995;86: 3848-3860.","DOI":"10.1182\/blood.V86.10.3848.bloodjournal86103848"},{"key":"2019111816075708900_REF55","doi-asserted-by":"crossref","unstructured":"Ju ST, Panka DJ, Cui H, et al. Fas(CD95)\/FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373: 444-448.","DOI":"10.1038\/373444a0"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/7\/2863\/1338565\/zh800706002863.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/107\/7\/2863\/1338565\/zh800706002863.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T20:10:36Z","timestamp":1683317436000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/107\/7\/2863\/132036\/CD7restricted-activation-of-Fasmediated-apoptosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,1]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2006,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-07-2929","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,1]]}}}